[HTML][HTML] Recent advances in targeted therapy for pancreatic adenocarcinoma
YT Fang, WW Yang, YR Niu, YK Sun - World journal of …, 2023 - ncbi.nlm.nih.gov
Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …
Recent advances in targeted therapy for pancreatic adenocarcinoma.
YT Fang, WW Yang, YR Niu, YK Sun - World Journal of …, 2023 - europepmc.org
Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …
Recent advances in targeted therapy for pancreatic adenocarcinoma
YT Fang, WW Yang, YR Niu… - World journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …
WJGO
YT Fang, WW Yang, YR Niu, YK Sun - 2023 - europepmc.org
Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …